Cited 26 times in
Involved-field radiation therapy for recurrent ovarian cancer: Results of a multi-institutional prospective phase II trial
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 김용배 | - |
dc.contributor.author | 장지석 | - |
dc.contributor.author | 김상운 | - |
dc.date.accessioned | 2018-11-07T16:40:35Z | - |
dc.date.available | 2018-11-07T16:40:35Z | - |
dc.date.issued | 2018 | - |
dc.identifier.issn | 0090-8258 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/165091 | - |
dc.description.abstract | OBJECTIVE: To evaluate the efficacy and safety of involved-field radiation therapy (IFRT) in patients with locoregionally confined recurrent or persistent epithelial ovarian cancer. METHODS: This study included patients with recurrent epithelial ovarian cancer eligible for IFRT either during diagnosis of the recurrence or after salvage therapies. IFRT was performed at a dose of ≥45 Gy for all tumors with 10-15-mm margins as seen on standard imaging. The primary endpoint was progression-free survival (PFS); the secondary endpoints were safety, response rate, local control, and overall survival (OS). RESULTS: Thirty patients with a mean number of 5.7 metastatic lesions each were enrolled between 2014 and 2016. Seventeen were treated with 3-D conformal radiation therapy (RT) and 13 with intensity-modulated RT. IFRT was well tolerated in all patients, and acute toxicity ≥ grade 2 was not observed. One case of grade 3 abdominal pain was reported 10 months post-RT. The overall and complete response rates were 85.7% and 50%, respectively. After a median follow-up of 28 (range, 17-42) months, the median PFS was 7 months. The 2-year PFS rate was 39.3%. Six of the 16 patients who developed outfield disease progression after IFRT were successfully treated with repeat IFRT as salvage treatment. The 3-year local control and OS rates were 84.4% and 55.8%, respectively. CONCLUSIONS: Although the primary endpoint was not met, IFRT might be safe and effective for in-field tumor control in patients with persistent epithelial ovarian cancer with a limited number of metastatic foci. We plan to conduct a larger scale multi-center phase II prospective study. | - |
dc.description.statementOfResponsibility | restriction | - |
dc.language | English | - |
dc.publisher | Academic Press | - |
dc.relation.isPartOf | GYNECOLOGIC ONCOLOGY | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.rights | https://creativecommons.org/licenses/by-nc-nd/2.0/kr/ | - |
dc.title | Involved-field radiation therapy for recurrent ovarian cancer: Results of a multi-institutional prospective phase II trial | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Urology (비뇨의학교실) | - |
dc.contributor.googleauthor | Jee Suk Chang | - |
dc.contributor.googleauthor | Sang Wun Kim | - |
dc.contributor.googleauthor | Yeon-Joo Kim | - |
dc.contributor.googleauthor | Joo-Young Kim | - |
dc.contributor.googleauthor | Sang-Yoon Park | - |
dc.contributor.googleauthor | Jin Hee Kim | - |
dc.contributor.googleauthor | Tae-Kyu Jang | - |
dc.contributor.googleauthor | Yong Bae Kim | - |
dc.identifier.doi | 10.1016/j.ygyno.2018.08.012 | - |
dc.contributor.localId | A00527 | - |
dc.contributor.localId | A00744 | - |
dc.contributor.localId | A04658 | - |
dc.relation.journalcode | J00956 | - |
dc.identifier.eissn | 1095-6859 | - |
dc.identifier.pmid | 30146110 | - |
dc.identifier.url | https://www.sciencedirect.com/science/article/pii/S0090825818311296 | - |
dc.subject.keyword | Ovarian cancer | - |
dc.subject.keyword | Radiation therapy | - |
dc.subject.keyword | Recurrent | - |
dc.contributor.alternativeName | Kim, Sang Woon | - |
dc.contributor.alternativeName | Kim, Yong Bae | - |
dc.contributor.alternativeName | Chang, Jee Suk Paul | - |
dc.contributor.affiliatedAuthor | 김용배 | - |
dc.contributor.affiliatedAuthor | 장지석 | - |
dc.citation.volume | 151 | - |
dc.citation.number | 1 | - |
dc.citation.startPage | 39 | - |
dc.citation.endPage | 45 | - |
dc.identifier.bibliographicCitation | GYNECOLOGIC ONCOLOGY, Vol.151(1) : 39-45, 2018 | - |
dc.identifier.rimsid | 60276 | - |
dc.type.rims | ART | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.